PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32082103-0	2019	Corrigendum: 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.	2-pyrrolidone	13-28	4-aminobutyrate aminotransferase	Homo sapiens	82-99	
31133775-10	2019	In the analysis of clinical EDTA plasma samples, the levels of succinimide and 2-pyrrolidinone showed a high level of correlation (R = 0.73), indicating impairment in GABA metabolism and further supporting the association with GABA-transaminase deficiency and the pathogenicity of the ABAT variants.	2-pyrrolidone	79-94	4-aminobutyrate aminotransferase	Homo sapiens	227-244	
31133775-10	2019	In the analysis of clinical EDTA plasma samples, the levels of succinimide and 2-pyrrolidinone showed a high level of correlation (R = 0.73), indicating impairment in GABA metabolism and further supporting the association with GABA-transaminase deficiency and the pathogenicity of the ABAT variants.	2-pyrrolidone	79-94	4-aminobutyrate aminotransferase	Homo sapiens	285-289	
31133775-11	2019	Further analysis of metabolomic data across our patient population revealed the association of elevated levels of 2-pyrrolidinone with administration of vigabatrin, a commonly used anti-seizure medication and a known inhibitor of GABA-transaminase.	2-pyrrolidone	114-129	4-aminobutyrate aminotransferase	Homo sapiens	230-247